Mizuho Raises UiPath (NYSE:PATH) Price Target to $25.00

UiPath (NYSE:PATH) had its price objective increased by Mizuho from $22.00 to $25.00 in a report released on Thursday, Benzinga reports. Mizuho currently has a neutral rating on the healthcare company’s stock.

Other research analysts also recently issued reports about the company. Canaccord Genuity Group lifted their price target on UiPath from $27.00 to $30.00 and gave the stock a buy rating in a research report on Friday. BMO Capital Markets boosted their price objective on UiPath from $24.00 to $28.00 and gave the company a market perform rating in a research report on Thursday. Royal Bank of Canada boosted their price objective on UiPath from $27.00 to $29.00 and gave the company a sector perform rating in a research report on Thursday. Needham & Company LLC boosted their price objective on UiPath from $25.00 to $30.00 and gave the company a buy rating in a research report on Thursday. Finally, Morgan Stanley boosted their price objective on UiPath from $17.00 to $25.00 and gave the company an equal weight rating in a research report on Thursday. Nine research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of Hold and a consensus target price of $27.13.

UiPath Stock Up 1.4 %

NYSE PATH traded up $0.32 during trading on Thursday, hitting $23.07. The company’s stock had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. The firm has a 50 day moving average price of $23.52 and a 200 day moving average price of $20.70. The firm has a market cap of $13.06 billion, a P/E ratio of -135.46 and a beta of 0.97. UiPath has a 52 week low of $12.38 and a 52 week high of $27.87.

Insiders Place Their Bets

In other UiPath news, Director Rich Wong sold 200,000 shares of the business’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $23.12, for a total value of $4,624,000.00. Following the transaction, the director now owns 429,418 shares of the company’s stock, valued at $9,928,144.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Rich Wong sold 200,000 shares of the company’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the transaction, the director now owns 429,418 shares of the company’s stock, valued at $9,928,144.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Ashim Gupta sold 70,000 shares of the company’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $23.02, for a total value of $1,611,400.00. Following the transaction, the chief financial officer now directly owns 788,148 shares in the company, valued at approximately $18,143,166.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 411,000 shares of company stock valued at $9,418,670. 31.03% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On UiPath

Several large investors have recently made changes to their positions in the company. Mark Sheptoff Financial Planning LLC acquired a new position in UiPath in the fourth quarter valued at about $25,000. HighMark Wealth Management LLC acquired a new position in UiPath in the fourth quarter valued at about $27,000. Tyler Stone Wealth Management acquired a new position in UiPath in the second quarter valued at about $28,000. Cypress Capital Management LLC WY acquired a new position in UiPath in the fourth quarter valued at about $29,000. Finally, Fifth Third Bancorp increased its holdings in shares of UiPath by 2,005.3% in the third quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock worth $34,000 after acquiring an additional 1,905 shares in the last quarter. Institutional investors and hedge funds own 59.04% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.